For example, the gene BRAF, which carries an activating mutation in about 50% of melanoma,4 occurs as a splice variant lacking exon 4–8, resulting in a loss of the RAS‐binding domain and therefore resistance against respective inhibitors.5 Here, BRAF is linked to melanoma.